TY - JOUR A2 - Buyukhatipoglu, Hakan AU - Ellis, H. P. AU - McInerney, C. E. AU - Schrimpf, D. AU - Sahm, F. AU - Stupnikov, A. AU - Wadsley, M. AU - Wragg, C. AU - White, P. AU - Prise, K. M. AU - McArt, D. G. AU - Kurian, K. M. PY - 2019 DA - 2019/12/31 TI - Clinically Actionable Insights into Initial and Matched Recurrent Glioblastomas to Inform Novel Treatment Approaches SP - 4878547 VL - 2019 AB - Glioblastoma is the most common primary adult brain tumour, and despite optimal treatment, the median survival is 12–15 months. Patients with matched recurrent glioblastomas were investigated to try to find actionable mutations. Tumours were profiled using a validated DNA-based gene panel. Copy number variations (CNVs) and single nucleotide variants (SNVs) were examined, and potentially pathogenic variants and clinically actionable mutations were identified. The results revealed that glioblastomas were idh.-野生型 ( idh. WT.; N = 38) and idh.- 压力( idh. mut; N = 3). SNVs in TSC2. MSH6. TP53 CREBBP., 和 IDH1.是预测在两个亚型中致病的未知意义(VUS)的变体。 idh. WT.肿瘤具有SNV,受影响RTK / RAS / PI(3)K,P53,WNT,SHH,NOTCH,RB和G蛋白途径。许多肿瘤有 BRCA1 / 2.(18%)变体,包括血管母细胞瘤中的确诊体细胞突变。 idh. WT.经常性肿瘤患有较少的途径(RTK / RAS / PI(3)K,P53,WNT和G蛋白)和CNV增益( BRCA2 GNA., 和 EGFR.)和损失( 塔特 Smarca4.)。 idh. mut肿瘤具有抗冲击/ RAS / PI(3)K,P53和WNT途径的SNV。vus in. klk1.可能是致病性的 idh. mut。经常性肿瘤的途径较少(P53,WNT和G蛋白)受到遗传改变的影响。公共数据集(TCGA和GDC)确认了两种亚型中发现的临床意义。总体而言,在这种队列中,潜在可操作的变化最常被识别 EGFR. PTEN. BRCA1 / 2., 和 atm。本研究强调了详细分子分析的需要,以确定可能有资格进行新型治疗方法的单个GBM患者。该信息对于患者招募患者至关重要。SN - 1687-8450 UR - https://doi.org/10.1155/2019/4878547 do - 10.1155 / 2019/4878547 jf - 肿瘤学杂志Pb - Hindawi Kw - ER -